Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TMS Co., Ltd. ( (JP:4891) ) has issued an update.
TMS Co., Ltd. announced the approval of the Clinical Trial Application by China’s National Medical Products Administration for the global ORION study, which examines the effects of JX10 (TMS-007) on acute ischemic stroke patients. This approval marks a significant step for TMS as it partners in this global study aimed at extending treatment opportunities and improving outcomes for stroke patients. The study is expected to have implications for the company’s operations and industry positioning, especially in the context of their ongoing global evaluation of JX10.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company that focuses on developing transformative medicines to treat serious diseases with high unmet medical needs. Its pipeline includes small molecule compounds known as SMTPs, derived from a fungus, and covers areas like acute ischemic stroke, hypertension, acute kidney injury, and spinal cord injury. The company’s lead program, TMS-007 (JX10), has shown promising results in Phase 2 trials for acute ischemic stroke.
YTD Price Performance: 14.22%
Average Trading Volume: 1,363,899
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: Yen10.32B
For an in-depth examination of 4891 stock, go to TipRanks’ Stock Analysis page.